Free Trial

Gilead Sciences (GILD) Competitors

Gilead Sciences logo
$108.22 -0.58 (-0.53%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$109.00 +0.78 (+0.72%)
As of 07/18/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GILD vs. LGND, MRNA, REGN, VIR, VRTX, ABBV, MRK, PFE, AMGN, and ALNY

Should you be buying Gilead Sciences stock or one of its competitors? The main competitors of Gilead Sciences include Ligand Pharmaceuticals (LGND), Moderna (MRNA), Regeneron Pharmaceuticals (REGN), Vir Biotechnology (VIR), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Amgen (AMGN), and Alnylam Pharmaceuticals (ALNY). These companies are all part of the "medical" sector.

Gilead Sciences vs. Its Competitors

Ligand Pharmaceuticals (NASDAQ:LGND) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

Gilead Sciences has a net margin of 20.76% compared to Ligand Pharmaceuticals' net margin of -73.07%. Gilead Sciences' return on equity of 51.93% beat Ligand Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Ligand Pharmaceuticals-73.07% -7.83% -6.92%
Gilead Sciences 20.76%51.93%17.40%

Ligand Pharmaceuticals currently has a consensus price target of $147.17, suggesting a potential upside of 5.80%. Gilead Sciences has a consensus price target of $111.38, suggesting a potential upside of 2.92%. Given Ligand Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Ligand Pharmaceuticals is more favorable than Gilead Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ligand Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
Gilead Sciences
0 Sell rating(s)
9 Hold rating(s)
14 Buy rating(s)
3 Strong Buy rating(s)
2.77

91.3% of Ligand Pharmaceuticals shares are held by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are held by institutional investors. 7.0% of Ligand Pharmaceuticals shares are held by insiders. Comparatively, 0.3% of Gilead Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Gilead Sciences has higher revenue and earnings than Ligand Pharmaceuticals. Ligand Pharmaceuticals is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ligand Pharmaceuticals$167.13M16.05-$4.03M-$7.12-19.54
Gilead Sciences$28.75B4.68$480M$4.7522.78

In the previous week, Gilead Sciences had 55 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 67 mentions for Gilead Sciences and 12 mentions for Ligand Pharmaceuticals. Gilead Sciences' average media sentiment score of 0.82 beat Ligand Pharmaceuticals' score of 0.77 indicating that Gilead Sciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ligand Pharmaceuticals
6 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Gilead Sciences
39 Very Positive mention(s)
2 Positive mention(s)
11 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Positive

Ligand Pharmaceuticals has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.29, indicating that its share price is 71% less volatile than the S&P 500.

Summary

Gilead Sciences beats Ligand Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

Get Gilead Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GILD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GILD vs. The Competition

MetricGilead SciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$135.34B$2.95B$5.55B$9.40B
Dividend Yield2.90%2.47%3.75%4.03%
P/E Ratio22.7819.7528.0119.82
Price / Sales4.68300.24432.8198.20
Price / Cash15.8442.5936.1658.27
Price / Book7.017.678.125.65
Net Income$480M-$55.28M$3.25B$257.91M
7 Day Performance-1.30%4.85%1.68%3.38%
1 Month Performance0.20%11.70%7.30%11.11%
1 Year Performance49.15%3.69%32.89%18.99%

Gilead Sciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GILD
Gilead Sciences
4.8922 of 5 stars
$108.22
-0.5%
$111.38
+2.9%
+47.2%$135.34B$28.75B22.7817,600Trending News
Insider Trade
Analyst Revision
LGND
Ligand Pharmaceuticals
3.5262 of 5 stars
$125.80
+3.4%
$147.17
+17.0%
+40.6%$2.43B$181.49M-17.6680
MRNA
Moderna
4.2582 of 5 stars
$32.89
-2.2%
$46.61
+41.7%
-74.2%$12.72B$3.24B-3.775,800Trending News
Options Volume
Analyst Revision
REGN
Regeneron Pharmaceuticals
4.7754 of 5 stars
$571.87
+0.7%
$814.57
+42.4%
-49.2%$61.71B$14.09B14.5515,106
VIR
Vir Biotechnology
3.5796 of 5 stars
$5.50
-2.7%
$30.25
+450.5%
-47.1%$761.01M$74.21M-1.30580News Coverage
VRTX
Vertex Pharmaceuticals
4.7268 of 5 stars
$472.55
+0.8%
$511.71
+8.3%
-5.8%$121.41B$11.02B-120.616,100Positive News
Analyst Revision
ABBV
AbbVie
4.8295 of 5 stars
$191.31
-0.6%
$211.29
+10.4%
+10.6%$338.31B$56.33B81.5055,000Trending News
Ex-Dividend
Analyst Revision
MRK
Merck & Co., Inc.
4.9955 of 5 stars
$83.80
+0.5%
$108.69
+29.7%
-35.6%$210.35B$64.17B12.1975,000Positive News
PFE
Pfizer
4.9618 of 5 stars
$25.42
-0.9%
$28.55
+12.3%
-17.7%$144.51B$62.46B18.4281,000Trending News
AMGN
Amgen
4.3997 of 5 stars
$296.13
+0.3%
$307.82
+3.9%
-10.9%$159.21B$33.42B27.0228,000Trending News
Analyst Revision
ALNY
Alnylam Pharmaceuticals
4.0395 of 5 stars
$316.71
+0.6%
$345.70
+9.2%
+35.4%$41.29B$2.25B-151.522,230News Coverage
Analyst Forecast
Analyst Revision

Related Companies and Tools


This page (NASDAQ:GILD) was last updated on 7/19/2025 by MarketBeat.com Staff
From Our Partners